Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Zhang, Huili ^a   Guo, Changfa ^b   Wu, Duojiao ^b   Zhang, Alian ^a   Gu, Ting ^a   Wang, Liansheng ^a   Wang, Changqian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CYSTATHIONINE GAMMA LYASE; FRACTALKINE; GAMMA INTERFERON; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROPARGYLGLYCINE; RANTES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CATALYSIS; CELL CULTURE; CELL STRAIN; CELLULAR DISTRIBUTION; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; LIPID DIET; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANIMALS; AORTA; ATHEROSCLEROSIS; CATALYSIS; CHEMOKINE CX3CL1; CHEMOTAXIS; CYSTATHIONINE GAMMA-LYASE; DOWN-REGULATION; GENE EXPRESSION REGULATION; HYDROGEN SULFIDE; INTERFERON-GAMMA; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; RECEPTORS, CHEMOKINE;

MUS;

EID: 84864011340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041147     Document Type: Article

References (38)

1. Renga B, (2011) Hydrogen sulfide generation in mammals: the molecular biology of cystathionine-β-synthase (CBS) and cystathionine-γ-lyase (CSE). Inflamm Allergy Drug Targets 10: 85-91.
2. Lefer DJ, (2007) A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci 104: 17907-17908.
3. Elsey DJ, Fowkes RC, Baxter GF, (2010) Regulation of cardiovascular cell function by hydrogen sulfide (H2S). Cell Biochem Funct 28: 95-106.
4. Wang Y, Zhao X, Jin H, Wei H, Li W, et al. (2009) Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 29: 173-179.
5. Zhao ZZ, Wang Z, Li GH, WanG R, Tan JM, et al. (2011) Hydrogen sulfide inhibits macrophage-derived foam cell formation. Exp Biol Med (Maywood) 236: 169-176.
6. Meng QH, Yang G, Yang W, Jiang B, Wu L, et al. (2007) Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries. Am J Pathol 170: 1406-1414.
7. Charo IF, Ransohoff RM, (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621.
8. Zernecke A, Shagdarsuren E, Weber C, (2008) Chemokine in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 28: 1897-1908.
9. Tacke F, Alvarez D, Kaplan J, Jakubzick C, Spanbroek R, et al. (2007) Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117: 185-194.
10. Zhao Q, (2010) Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 88: 41-55.
11. Wong BW, Wong D, McManus BM, (2002) Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 11: 332-338.
12. Boring L, Gosling J, Cleary M, Charo IF, (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394: 894-897.
13. Dawson TC, Kuziel WA, Osahar TA, Maeda N, (1999) Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143: 205-211.
14. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, et al. (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27: 373-379.
15. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, et al. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94: 253-261.
16. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, et al. (2008) A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28: 1090-1096.
17. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, et al. (2004) Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 101: 17795-17800.
18. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, et al. (2003) Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107: 1009-1016.
19. Lesnik P, Haskell CA, Charo IF, (2003) Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111: 333-340.
20. Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, et al. (2009) High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 30: 1773-1778.
21. Barlic J, Zhang Y, Foley JF, Murphy PM, (2006) Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway. Circulation 114: 807-819.
22. Barlic J, Murphy PM, (2007) An oxidized lipid-PPARγ-chemokine pathway in the regulation of macrophage: vascular smooth muscle cell adhesion. Trends Cardiovasc Med 17: 269-274.
23. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK, (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82.
24. Bhavsar PK, Sukkar MB, Khorasani N, Lee KY, Chung KF, (2008) Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-κB. FASEB J 22: 1807-1816.
25. Zhi L, Ang AD, Zhang H, Moore PK, Bhatia M, (2007) Hydrogen sulfide induces the synthesis of proinflammatory cytokines in human monocyte cell line U937 via the ERK-NF-kappaB pathway. J Leuk Biol 81: 1322-1332.
26. Oh GS, Pae HO, Lee BS, Kim BN, Kim JM, et al. (2006) Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. Free Radic Biol Med 41: 106-119.
27. Hu LF, Wong PTH, Moore PK, Bian JS, (2007) Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogenactivated protein kinase in microglia. J Neurochem 100: 1121-1128.
28. Wan Y, Evans RM, (2010) Rosiglitazone activation of PPARγ suppresses fractalkine signaling. J Mol Endocrinol 44: 135-142.
29. Kimura Y, Kimura H, (2004) Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18: 1165-1167.
30. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, et al. (2004) The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? J Neurochem 90: 765-768.
31. Whiteman M, Li L, Kostetski I, Chu SH, Siau JL, et al. (2006) Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem Biophys Res Commun 343: 303-310.
32. Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, et al. (2002) Nitration of PPARγ inhibits ligand-dependent translocation into the nucleus in a macrophage-like cell line, RAW 264. FEBS Lett 525: 43-47.
33. Wang Q, Tang C, Jin H, Du J, (2010) Endogenous hydrogen sulfide is involved in the pathogenesis of atherosclerosis. Biochem Biophys Res Commun 396: 182-186.
34. Zhang H, Zhi L, Moochhala SM, Moore PK, Bhatia M, (2007) Endogenous hydrogen sulfide regulates leukocyte trafficking in cecal ligation and puncture-induced sepsis. J Leukoc Biol 82: 894-905.
35. Zhang H, Zhi L, Moore PK, Bhatia M, (2006) Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am J Physiol Lung Cell Mol Physiol 290: L1193-L1201.
36. Gan LM, Grönros J, Hägg U, Wikström J, Theodoropoulos C, et al. (2007) Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. Atherosclerosis 190: 313-320.
37. Wu DJ, Xu JZ, Wu YJ, Jean-Charles L, Xiao B, et al. (2009) Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis 207: 68-73.
38. Johnson J, Carson K, Williams H, Karanam S, Newby A, et al. (2005) Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 111: 1422-1430.